Table 2.
Assignment of DE-genes to canonical pathways in the comparison between breeds at either 63 dpc or 91 dpc
| Ingenuity Canonical Pathways | PI vs. GL at 63 dpc or 91 dpc | p-value1 | Ratio2 | Molecules | |
|---|---|---|---|---|---|
| Clathrin-mediated Endocytosis Signaling |
63 |
0.011 |
0.222 |
EPS15, STON2, CDC42, FGF2, ARPC5, NUMB, SH3GL2, ITGB8, PIK3R4, CD2AP, ACTR3, WASL, SNX9, IGF1, PIK3C3, ARPC3, DAB2, STAM, AAK1, PPP3CA, ACTA1, ATM, ITGB1, MYO6, ACTR2, PIK3C2A, SH3GL3, ACTB, CLTC, RAB7A, MET, CBL, SYNJ1, ARPC2, RAB11A, TFRC, UBC, PDGFD |
|
| 91 |
0.106 |
0.029 |
EPS15, FGF2, TFRC, DAB2, AAK1 |
||
| Corticotropin Releasing Hormone Signaling |
63 |
0.033 |
0.204 |
RAP1B, PRKACB, RAF1, MAPK1, ARPC5, CREB5, PRKAG1, PRKD3, PRKCA, null, ITPR2, CNR1, PTCH1, GNAQ, GNAI1, ADCY6, MAPK12, RAP1A, ATF2, GNAS, GNAI3, PRKCI, MAPK14, PRKAR2B, PRKAG2, PRKCH, GLI1, PRKCB |
|
| 91 |
0.258 |
0.022 |
PRKAR2B, ADCY3, PTGS2 |
||
| Integrin Signaling |
63 |
0.000 |
0.259 |
MAP2K4, RAP2B, RAF1, MYL2, MAPK1, ARPC5, ITGA8, KRAS, PIK3R4, PTEN, TSPAN3, RHOG, ARF4, CAV1, ITGAV, GSK3B, ACTA1, ATM, CAPN5, ACTR2, BCAR3, RAP1A, TTN, RHOQ, RND3, ARPC2, PPP1R12A, CAPN7, TSPAN6, RAP1B, FYN, PPP1CC, RALA, CDC42, PPP1CB, ITGB8, SHC1, ACTR3, WASL, RHOT1, PIK3C3, SOS1, ARPC3, ITGB1, PAK2, PIK3C2A, ASAP1, ACTB, ITGA2, MAPK8, ROCK1, WIPF1, ITGAX |
|
| |
91 |
0.191 |
0.024 |
RALA, ASAP1, ARF4, ITGA8, TTN |
|
| PI3K/AKT Signaling |
63 |
0.048 |
0.197 |
RAF1, MAPK1, INPPL1, KRAS, JAK2, MAP3K5, EIF4E, PTEN, BCL2, SHC1, IKBKG, SOS1, TSC2, GSK3B, MCL1, ITGB1, RPS6KB1, YWHAG, PPP2R5C, ITGA2, TYK2, YWHAZ, PPP2R5A, PPP2CB, GAB1, CDKN1B, PPP2R5E, PPP2R1B |
|
| 91 |
0.296 |
0.021 |
PTGS2, PPP2R5A, BCL2 |
||
| α-Adrenergic Signaling |
63 |
0.012 |
0.236 |
PRKACB, RAF1, MAPK1, GNB5, KRAS, PRKAG1, PHKA2, GNB1, GNB4, PHKB, PRKD3, PRKCA, null, ITPR2, GNAI1, ADCY6, GNAQ, GNAS, GNAI3, PRKCI, PRKAR2B, PRKAG2, PRKCH, GNG2, PRKCB |
|
| 91 |
0.404 |
0.019 |
PRKAR2B, ADCY3 |
||
| IL-15 Signaling |
63 |
0.047 |
0.229 |
STAT5A, RAF1, PIK3C2A, MAPK1, TYK2, KRAS, JAK2, AXL, MAPK12, PIK3R4, BCL2, SHC1, MAPK14, PIK3C3, SYK, ATM |
|
| 91 |
0.267 |
0.029 |
STAT6, BCL2 |
||
| Myc Mediated Apoptosis Signaling |
63 |
0.018 |
0.266 |
MAP2K4, YWHAG, PIK3C2A, MAPK8, YWHAZ, MAPK9, KRAS, PIK3R4, MAPK12, BCL2, SHC1, IGF1, PIK3C3, SOS1, CYCS, BID, ATM |
|
| 91 |
0.255 |
0.031 |
APAF1, BCL2 |
||
| Protein Kinase A Signaling |
63 |
0.000 |
0.228 |
PRKACB, MYH10, RAF1, TGFBR1, MAPK1, MYL2, PDE12, GNB5, AKAP3, CREB5, PPP1R14B, TGFBR2, GNB1, GNB4, PHKB, CAMK2A, TDP2, GSK3B, PRKD3, null, YWHAG, ITPR2, PTCH1, CREBBP, YWHAZ, RAP1A, MYL6B, TTN, ATF2, MYL9, AKAP13, ANAPC4, ANAPC5, PPP1R12A, PRKCH, LEF1, GNG2, PDE6D, AKAP12, RAP1B, PPP1CC, FLNB, PDE7A, AKAP8, PDIA3, PPP1CB, H3F3A/H3F3B, CDC23, PRKAG1, PHKA2, NFAT5, TGFB2, SMAD4, PPP3CA, PRKCA, AKAP5, ATF1, MAP3K1, ADCY6, GNAI1, GNAQ, ANAPC13, ROCK1, GNAS, GNAI3, PPP1R3D, PRKAR2B, PRKCI, ADD3, KDELR2, PRKAG2, AKAP9, PRKCB, ANAPC1 |
|
| 91 |
0.348 |
0.019 |
ADD3, PRKAR2B, ADCY3, AKAP3, AKAP7, TTN |
||
| Molecular Mechanisms of Cancer |
63 |
0.000 |
0.275 |
RAP2B,RAF1,TGFBR1,APH1B,TAB2,ARHGEF1,KRAS,RBL1,RB1,CAMK2A,HIPK2,PRKD3,ATM,SMAD2,TFDP1,PTCH1,CREBBP,RAP1A,CDH1,GAB1,E2F1,CYCS,CFLAR,RAP1B,FYN,RALA,CDC42,LRP6,BMPR2,CRK,JAK2,MAP3K5,GNA14,CHEK1,CASP6,PIK3C3,SOS1,E2F5,BID,BMP1,PAK2,GNAQ,ADCY6,MAPK8,GNAI3,RBPJ,ATR,BIRC2,PSEN1,PRKCB,MAP2K4,PRKACB,MAPK1,PIK3R4,TGFBR2,RHOG,GSK3B,RASA1,BIRC3,TYK2,CDK6,MAPK12,RALBP1,APC,RHOQ,CBL,PTPN11,RND3,FZD6,PRKCH,LEF1,FZD5,CDK2,HIF1A,E2F3,PRKAG1,BCL2,CDC25B,SHC1,FANCD2,RHOT1,BMPR1A,MAP3K7,TGFB2,SMAD4,PRKCA,ARHGEF12,PIK3C2A,HAT1,GNAI1,MAPK9,XIAP,GNAS,PRKCI,MAPK14,PRKAR2B,FZD4,NF1,BMP8B,PRKAG2,CDKN1B,GLI1,BCL2L11 |
|
| 91 |
0.017 |
0.029 |
PRKAR2B,RALA,FZD4,ADCY3,APAF1,RAPGEF3,E2F3,CASP7,E2F2,WNT5A,BCL2 |
||
| p53 Signaling |
63 |
0.000 |
0.293 |
GADD45G, PIK3R4, PTEN, CHEK1, BCL2, RB1, CASP6, GADD45A, PIK3C3, GSK3B, HIPK2, ATM, TP53INP1, TP63, PIK3C2A, TOPBP1, MED1, THBS1, HDAC1, PERP, MAPK8, TP53BP2, KAT2B, PCNA, MAPK14, E2F1, ATR, CDK2, SIRT1 |
|
| 91 |
0.192 |
0.030 |
MED1, APAF1, BCL2 |
||
| VDR/RXR Activation |
63 |
0.003 |
0.284 |
CYP24A1, SPP1, CCNC, MED1, IGFBP5, CEBPB, THBD, KLF4, NCOA3, GTF2B, PRKCI, SP1, GADD45A, NCOA2, MXD1, NCOA1, IGFBP3, TGFB2, PRKCH, CDKN1B, PRKD3, PRKCA, PRKCB |
|
| 91 |
0.124 |
0.037 |
CYP24A1, MED1, MXD1 |
||
| Breast Cancer Regulation by Stathmin1 |
63 |
0.000 |
0.248 |
PRKACB, RAF1, CAMK1D, MAPK1, GNB5, KRAS, ARHGEF1, PIK3R4, PPP1R14B, GNB1, GNB4, CAMK2A, PRKD3, ATM, null, ITPR2, PPP2CB, E2F1, PPP1R12A, PRKCH, GNG2, CDK2, PPP1CC, CDC42, PPP1CB, E2F3, PRKAG1, SHC1, PIK3C3, SOS1, RB1CC1, E2F5, PRKCA, ARHGEF12, PIK3C2A, PPP2R5C, GNAI1, TUBA4A, ADCY6, GNAQ, PPP2R5A, ROCK1, GNAS, GNAI3, PPP1R3D, PRKCI, PRKAR2B, PRKAG2, CDKN1B, PPP2R5E, PPP2R1B, PRKCB |
|
| 91 |
0.191 |
0.024 |
PRKAR2B, ADCY3, E2F3, E2F2, PPP2R5A |
||
| ERK/MAPK Signaling |
63 |
0.001 |
0.230 |
RAP1B, PRKACB, FYN, PPP1CC, RAF1, MAPK1, HSPB2, H3F3A/H3F3B, ETS2, PPP1CB, KRAS, CRK, PIK3R4, CREB5, PPP1R14B, EIF4E, PRKAG1, SHC1, PIK3C3, SOS1, MKNK1, PRKCA, ATM, ITGB1, MYCN, PAK2, YWHAG, PPP2R5C, ATF1, PIK3C2A, ITGA2, YWHAZ, MAPKAPK5, RAP1A, PPP2R5A, ATF2, PLA2G4A, PPP2CB, PPP1R3D, PRKCI, PRKAR2B, PRKAG2, PPP1R12A, PPP2R5E, PPP2R1B, ELK3, PRKCB |
|
| 91 |
0.556 |
0.015 |
PRKAR2B, RAPGEF3, PPP2R5A |
||
| RAR Activation |
63 |
0.001 |
0.246 |
MAP2K4, PRKACB, NSD1, MAPK1, MAP3K5, JAK2,RBP1, PRKAG1, PTEN, PNRC1, TGFB2, SMAD4, GTF2H5, NR2F6, RDH13, PRKD3, CITED2, PRKCA, STAT5A, SMAD2, SRA1, PRMT2, IL3RA, RDH14, MED1, RDH11, MAP3K1, CREBBP, MAPK8, ADCY6, MAPK9, MAPK12, CRABP1, PARP1, KAT2B, PRKCI, MAPK14, PRKAR2B, TAF4, ERCC3, IGFBP3, NCOA1, PRKAG2, PRKCH, PRKCB |
|
| 91 | 0.269 | 0.022 | PRKAR2B, MED1, ADCY3, RDH13 |
1pathways are shown that were significant at p < 0.05 according to Fishers exact test in at minimum one of the three types of comparisons.
2ratio of number of differentially expression genes assigned to the pathway and the total number of genes assigned to the pathway in the Ingenuity Knowledge Base.